Top News from ECCMID 2018

Top News from the 28th Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in Madrid, Spain – ECCMID 2018

Motif Bio Presented New Iclaprim Data

April 22, 2018

Motif Bio plc, a clinical-stage biopharmaceutical company specializing in developing novel antibiotics, announced that new clinical and pre-clinical data with its investigational drug candidate iclaprim were presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018). The REVIVE-2 study was a global Phase 3 trial evaluating iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI). As previously reported, the study met its primary endpoint of non-inferiority (NI) (10% margin) compared to vancomycin, the current standard of care, at the early time point (ETP), 48 to 72 hours after the start of administration of the study drug, in the intent-to-treat (ITT) patient population. Iclaprim also achieved NI (10% margin) at the test of cure (TOC) endpoint, 7 to 14 days after study drug discontinuation, in the ITT patient population.

Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018

April 23, 2018

Melinta Therapeutics, Inc., a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, presented findings at ECCMID 18 meeting highlighting data for RX-P2382, an advanced lead investigational compound from the newly developed pyrrolocytosine class. Pyrrolocytosines were specifically designed by Melinta to target previously untapped binding sites on bacterial ribosomes and optimized for activity against today’s “superbugs”.

SCYNEXIS Data Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis

April 23, 2018

SCYNEXIS, Inc., a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, has announced data presented at ECCMID 2018. SCY-078, the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, is in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis. The Company also announced the publication of results from a study evaluating the activity of SCY-078 both alone and in combination with other antifungal therapies in over 300 Aspergillus strains in the journal Antimicrobial Agents and Chemotherapy.

Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations

April 23, 2018

Melinta Therapeutics, Inc., a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, has presented detailed results from the VABOMERE™ (meropenem and vaborbactam) Phase 3 TANGO II trial at the ECCMID 2018 meeting. The majority of patients enrolled in TANGO II presented at baseline with severe co-morbidities including compromised immune systems or renal insufficiency, each of which can complicate treatment and have a negative impact on clinical outcomes. At ECCMID, Melinta presented additional data from TANGO II highlighting outcomes in these vulnerable patient populations.

Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia Based on the EMA Guidelines

April 23, 2018

Paratek Pharmaceuticals, Inc. presented an analysis of data from the Company’s Phase 3 OPTIC study of omadacycline vs. moxifloxacin for the treatment of community-acquired bacterial pneumonia (CABP) using the European Medicines Agency (EMA) guidance for approval of new treatments for CABP.  Omadacycline is an investigational once-daily oral and intravenous (IV) monotherapy antibiotic for the treatment of community-acquired infections including CABP and acute bacterial skin and skin structure infections (ABSSSI). Paratek plans to submit its marketing authorizations for omadacycline in Europe in the second half of 2018.

Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin)

April 23, 2018

Theravance Biopharma, Inc. has announced positive new data from multiple studies of VIBATIV® (telavancin). Two presentations were made reporting new data from the Telavancin Observational Use Registry (TOUR™) study, which is designed to report how VIBATIV® (telavancin) is being used by healthcare practitioners to treat patients in real-world clinical settings. The presented findings, which focus on data from registry patients classified as elderly or obese, report positive clinical responses for VIBATIV treatment ranging from 76.5% to 78.8% in these patient subgroups. Positive clinical response was defined as cure or improvement leading to step-down oral therapy.

Rebiotix Presents Posters Highlighting Microbiome Health Index™ Value Potential and RBX2660 Phase 2 Clinical Program Data

 

April 24, 2018

Rebiotix Inc. has announced the presentation of two posters during the ECCMID 2018. Collectively, the posters add to the growing library of data recently published and presented by Rebiotix highlighting the company’s microbiome drug products, clinical programs, and pioneering research involving microbiome composition and health. The first poster provided a comparative analysis from the Phase 2B (PUNCH CD2) and open-label Phase 2 (PUNCH SOS) clinical trials of RBX2660 for the prevention of recurrent C. diff infection (rCDI).  According to the researchers, the data collectively demonstrate the safety and the effectiveness of RBX2660 in preventing rCDI when compared to placebo-treated and historical control groups. In the second poster, the researchers explored the potential of the MHI to enable a non-biased comparison of the efficacy of microbiome-based therapeutics.

Cardiome Presented Fifteen Xydalba™ And Zevtera® Abstracts

April 24, 2018

Cardiome Pharma Corp., a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, announced that 15 data presentations took place at the ECCMID 2018. The presentations included data for the Company’s commercial anti-infective assets, Xydalba™ (dalbavancin hydrochloride) and Zevtera/Mabelio (ceftobiprole), an intravenous (IV) cephalosporin antibiotic with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.

Curetis Launched CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge

April 24, 2018

Curetis N.V., a developer of next-level molecular diagnostic solutions, has announced the successful completion of clinical performance evaluation and CE-IVD marking of its novel Unyvero Application Cartridge, UTI, for the diagnosis of severe urinary tract infections.

Basilea presented data on isavuconazole and ceftobiprole

April 24, 2018

Basilea Pharmaceutica Ltd. has announced that a broad range of posters and presentations on the antifungal isavuconazole (Cresemba®) and the antibiotic ceftobiprole (Zevtera®) were presented at the ECCMID 2018.

Top News from ECCMID 2018 last edit: 2018-04-30T22:04:40+00:00 da Luca

Leave a Reply

*The views and opinions expressed on IgeaHub belong to the authors only. They do not represent the views or opinions of any company or organization.

Follow Us

Join us

All rights reserved. Terms of use and Privacy Policy

Design by PT Webmaster

%d bloggers like this:
Skip to toolbar